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ABSTRACT
Sulindac is a commonly used nonsteroidal anti-inflammatory
drug. This study tested the hypothesis that sulindac-mediated
drug–drug interactions and/or hepatotoxicity may be caused,
in part, by inhibition of proteins responsible for the hepatic
transport of drugs and/or bile acids by sulindac and/or sulindac
metabolites [sulindac sulfone (S-sulfone) and sulindac sulfide
(S-sulfide)]. The uptake and excretion of model substrates,
[3H]taurocholate (TC), [3H]estradiol 17--glucuronide (E217G),
and nitrofurantoin (NF), were investigated in rat and human
suspended and sandwich-cultured hepatocytes (SCH). In sus-
pended rat hepatocytes, S-sulfone and S-sulfide inhibited Na-
dependent TC initial uptake (IC50 of 24.9  6.4 and 12.5  1.8
M, respectively) and Na-independent E217G initial uptake
(IC50 of 12.1  1.6 and 6.3  0.3 M, respectively). In rat SCH,
sulindac metabolites (100 M) decreased the in vitro biliary
clearance (Clbiliary) of TC, E217G, and NF by 38 to 83%, 81 to
97%, and 33 to 57%, respectively; S-sulfone and S-sulfide also
decreased the TC and NF biliary excretion index by 39 to 55%.
In suspended human hepatocytes, S-sulfone and S-sulfide in-
hibited Na-dependent TC initial uptake (IC50 of 42.2 and 3.1
M, respectively); S-sulfide also inhibited the TC Clbiliary in
human SCH. Sulindac/metabolites markedly inhibited hepatic
uptake and biliary excretion of E217G by 51 to 100% in human
SCH. In conclusion, sulindac and metabolites are potent inhib-
itors of the uptake and biliary clearance of bile acids in rat and
human hepatocytes and also inhibit substrates of rat breast
cancer resistance protein, rat and human organic anion-trans-
porting polypeptides, and human multidrug resistance-associ-
ated protein 2. Inhibition of multiple hepatic transport proteins
by sulindac/metabolites may play an important role in clinically
significant sulindac-mediated drug–drug interactions and/or
liver injury.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID)
indicated for the relief of signs and symptoms of arthritic
conditions, including osteoarthritis and rheumatoid arthri-
tis. Sulindac is reduced by the aldehyde oxidase system to
sulindac sulfide (S-sulfide) (Fig. 1), which has analgesic and
anti-inflammatory properties. S-sulfide is converted by fla-
vin-containing monooxygenase 3 back to sulindac and fur-
ther to sulindac sulfone (S-sulfone), which has been recog-
nized as a promising antiproliferative agent in colon cancer
(Tatsumi et al., 1983; Davies and Morris, 1993; Hamman et
al., 2000). Among NSAIDs, sulindac has been associated
most often with hepatotoxicity (Aithal and Day, 2007), par-
ticularly with cholestatic hepatitis, and to a lesser extent
with hepatocellular damage (Tarazi et al., 1993). Despite the
high incidence of liver injury, the mechanisms underlying
sulindac-mediated hepatotoxicity remain to be elucidated.
Inhibition of hepatic transport proteins has been pro-
posed as one mechanism of drug-induced liver injury
(DILI). Inhibition of the canalicular bile salt export pump
(BSEP) in rats (ABCB11) by hepatotoxic drugs such as trogli-
tazone and bosentan may lead to elevated hepatic concentra-
tions of detergent-like bile acids, which can disrupt cellular
function (Fattinger et al., 2001; Funk et al., 2001). Other he-
patic transport proteins also are involved in bile acid transport,
acting in concert to maintain homeostasis of bile acids. In hu-
mans, bile acids are taken up primarily by Na-dependent
taurocholate cotransporting polypeptide (NTCP; SLC10A1) and
Na-independent organic anion-transporting polypeptides
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(OATPs; SLCOs). Once taken up by hepatocytes, bile acids are
excreted into the canalicular lumen primarily by BSEP. Alter-
natively, bile acids can be excreted into sinusoidal blood by
basolateral hepatic transport proteins such as the multidrug
resistance-associated protein 3 (MRP3; ABCC) 3, MRP4, and
organic solute transporter / (Kosters and Karpen, 2008).
Some interactions between sulindac and hepatic transport
proteins have been demonstrated previously. Sulindac inhib-
ited organic anion transporter (OAT) 1-mediated [14C]para-
aminohippurate uptake (IC50 36 M) and OAT3-mediated
[3H]estrone sulfate uptake (IC50 3 M); sulindac also was
the most potent inhibitor among tested NSAIDs of organic
cation transporters 1 and 2 in stably transfected cells (Kham-
dang et al., 2002). Sulindac inhibited [3H]methotrexate
transport in MRP2- and MRP4-overexpressing membrane
vesicles (IC50 38 and 2 M, respectively) (El-Sheikh et al.,
2007). MRP2 functions to excrete compounds from the hepa-
tocyte into bile. In addition, S-sulfide was shown to be a
potent inhibitor of MRP4-mediated leukotriene B4 and C4
transport in MRP4-overexpressing membrane vesicles (Rius
et al., 2003). However, no studies demonstrating inhibition of
transport by sulindac/metabolites in rat or human hepato-
cytes have been reported.
Sulindac is metabolized extensively by the liver in rats and
humans, and plasma concentrations of sulindac metabolites
are sustained because of extensive enterohepatic recycling
(Dujovne et al., 1983). After intravenous administration of
sulindac (10 mg/kg) in rats, the plasma area under the con-
centration-time curve (AUC) for S-sulfone was 2.5-fold
higher than that of sulindac, whereas the AUC for S-sulfide
was only 40% of that for sulindac (Duggan et al., 1978);
Clbiliary of sulindac and S-sulfone were comparable, whereas
S-sulfide Clbiliary was only 40% of that for sulindac. In hu-
mans, after oral administration of sulindac, peak plasma
total concentrations (Cmax) for sulindac, S-sulfone, and S-
sulfide were 10 to 34, 4 to 19, and 3 to 33 M, respectively
(Davies and Morris, 1993); the apparent Clbiliary of sulindac
and S-sulfone, measured by an occludable T-tube that was
placed in the common bile duct of patients after elective
gallbladder surgery, was 25- and 18-fold greater, respec-
tively, than that of S-sulfide (Dobrinska et al., 1983). Several
groups have reported a proportional relationship between
S-sulfide concentrations and the incidence of hepatotoxicity,
emphasizing the potential for metabolites, in addition to the
parent drug, to cause hepatotoxicity (Duggan et al., 1978;
Laffi et al., 1986).
The present study was designed to examine the interac-
tion of sulindac and metabolites with hepatic transport
proteins in primary rat and human hepatocytes. To exam-
ine the effect of sulindac and metabolites on the function of
hepatic transport proteins, taurocholate was used as a
model substrate for Ntcp/NTCP and Bsep/BSEP, and es-
tradiol 17--glucuronide (E217G) was used as a model
substrate for Oatps/OATPs and Mrp2/MRP2 in rat and
human hepatocytes, respectively. In addition, nitrofuran-
toin (NF) was used to examine the interaction between
sulindac/metabolites and Bcrp.
Materials and Methods
Chemicals and Reagents. [3H]TC, [3H]E217G, and [14C]inulin
were purchased from PerkinElmer Life and Analytical Sciences
(Waltham, MA). Dulbecco’s modified Eagle’s medium (DMEM) and
minimum essential medium nonessential amino acids were pur-
chased from Invitrogen (Carlsbad, CA). BioCoat culture plates, Ma-
trigel extracellular matrix, and insulin/transferrin/selenium culture
supplement were purchased from BD Biosciences Discovery Labware
(Bedford, MA). NF, TC, E217G, sulindac, S-sulfone, S-sulfide, peni-
cillin-streptomycin solution, dexamethasone, Hanks’ balanced salt
solution (HBSS), modified HBSS (HBSS without Ca2 and Mg),
and Triton X-100 were purchased from Sigma-Aldrich (St. Louis,
MO). All other chemicals and reagents were of analytical grade and
were readily available from commercial sources.
Culture of Primary Rat and Human Hepatocytes in a Sand-
wich Configuration. Primary rat hepatocytes were cultured as
described previously (Lee et al., 2010). In brief, hepatocytes were
seeded at a density of 1.75  106 cells/well onto six-well BioCoat
plates. Approximately 24 h later, hepatocytes were overlaid with 2
ml of 0.25 mg/ml BD Matrigel basement membrane matrix in DMEM
containing 1% (v/v) insulin/transferrin/selenium culture supple-
ment, 0.1 M dexamethasone, 2 mM L-glutamine, 1% (v/v) minimum
essential medium nonessential amino acids, 100 units penicillin G
sodium/ml, and 100 g streptomycin sulfate/ml. CellzDirect
(Durham, NC) kindly provided human hepatocytes cultured in six-
well plates, seeded at a density of 1.5  106 cells/well, and overlaid
with Matrigel. Hepatocytes were cultured for 4 days (rat) or 7 to 8
days (human) to allow extensive formation of canalicular networks
between cells before experimentation; medium was changed daily.
Transport Studies Using Rat and Human Sandwich-Cul-
tured Hepatocytes. The method to determine substrate accumula-
tion in sandwich-cultured hepatocytes (SCH) has been described
Fig. 1. Chemical structures of sulindac (center), S-sulfone
(right), and S-sulfide (left).
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previously (Liu et al., 1999). In brief, SCH were washed twice with 2
ml of warm HBSS containing Ca2 (standard; cells  bile) or Ca2-
free HBSS (cells), followed by incubation in the same buffer for 10
min at 37°C. Subsequently, cells were incubated at 37°C for 10 min
with 1.5 ml of standard HBSS containing NF (5 M), [3H]TC (1 M;
100 nCi/ml), or [3H]E217G (1 M; 100 nCi/ml) in the presence of
sulindac or its metabolites (0–100 M). After 10 min, cells were
washed three times with ice-cold standard HBSS. Cells were lysed
with either 1 ml of methanol/water (70:30; v/v) (NF studies) or 0.5%
(v/v) Triton X-100 in phosphate-buffered saline (TC and E217G stud-
ies), and plates were shaken for at least 20 min. Samples of cells 
bile and cells were quantified by HPLC/MS/MS for NF and by liquid
scintillation spectroscopy (Packard Tricarb; PerkinElmer Life and
Analytical Sciences) for [3H]TC or [3H]E217G, and transport func-
tion was normalized to the protein content of the hepatocytes by
using a BCA protein assay (Pierce Chemical, Rockford, IL). The
biliary excretion index (BEI; %) and in vitro biliary clearance
(Clbiliary; ml/min/kg) were calculated by using B-CLEAR technology











where AUCmedium represents the area under the substrate concentra-
tion-time curve, which was determined by multiplying the initial sub-
strate concentration in the incubation medium by the incubation time
(10 min). Clbiliary values were converted to milliliter per minute per
kilogram based on previously reported values for protein content in
liver tissue (200 mg/g liver weight for rats; 160 mg/g liver weight for
humans) and liver weight (40 g/kg body weight for rats; 25.7 g/kg body
weight for humans) (Davies and Morris, 1993; Wilson et al., 2003).
HPLC/MS/MS Analysis of NF. NF accumulation in cells  bile
and cells was quantified by HPLC/MS/MS as described previously
(Yue et al., 2009). In brief, proteins were precipitated in samples
obtained from rat SCH by adding 1 ml of methanol/water (70:30, v/v),
and samples were sonicated for 20 s. After centrifugation at 4°C
(12,000g) for 3 min, the supernatant (20 l) was diluted with 100 l
of methanol and water containing internal standard (ethyl warfarin).
A Shimadzu (Columbia, MD) solvent delivery system and a LEAP
Technologies (Carrboro, NC) HTC Pal thermostated autosampler
connected to an Applied Biosystems (Foster City, CA) API 4000 triple
quadruple mass spectrometer with a Turbo Spray ion source were
used for analysis. NF and internal standards were eluted from an
Aquasil C18 column (50  2.1 mm, dp 
 5 m; Thermo Fisher
Scientific, Waltham, MA) using a mobile phase gradient (hold at
100% 10 mM ammonium acetate aqueous solution from 0 to 0.75
min; to 40% methanol from 0.75 to 1.39 min; to 90% methanol at
3.3 min; hold at 90% methanol until 4 min; equilibrated with 100% 10
mM ammonium acetate aqueous solution at 4 min; flow rate, 0.75
ml/min; 0.75 to 1.39 min directed to the mass spectrometer) and were
detected in negative ion mode by using multiple reaction monitoring:
NF, 236.83 151.8 m/z; ethyl warfarin, 320.83 160.9 m/z. Eight-point
calibration curves (2–1000 nM) were applied, and all points on the
curves were back-calculated to within  15% of the nominal value.
Transport Studies Using Suspended Primary Rat and Hu-
man Hepatocytes. The initial uptake of [3H]TC and [3H]E217G
was determined in freshly isolated hepatocytes, as described previ-
ously (Leslie et al., 2007). In brief, hepatocytes were washed twice
with ice-cold standard HBSS containing 10 mM Tris and 5 mM
glucose (Na-containing condition) or Na-free choline buffer. Hepa-
tocytes were suspended at 1  106 cells/ml in the same buffer and
used immediately in experiments. Hepatocytes (2 ml) in 16 
100-mm test tubes were incubated at 37°C in an orbital shaking
water bath for 3 min. Vehicle control (0.1% DMSO), S-sulfone, or
S-sulfide (0.1–100 M) was added, followed by [3H]TC (1 M; 60
nCi/ml) or [3H]E217G (1 M; 60 nCi/ml). At 30 s (TC) or 90 s
(E217G), samples (200 l) were placed into 0.4-ml polyethylene tubes
prefilled with 3 M KOH (50 l) layered with silicone oil/mineral oil
(82:18, v/v; 100 l) and immediately centrifuged. Radioactivity in the
cell pellet and supernatant was quantified by liquid scintillation
counting and corrected for the adherent fluid volume, which was
determined by the incubation of cells with [14C]inulin (Brouwer et
al., 1987). At the end of each experiment, an aliquot (10 l) of
suspended cells was used to determine protein concentrations by the
BCA protein assay.
Determination of Inhibitory Potency of Sulindac Metabo-
lites on Na-Dependent [3H]TC Uptake or Na-Independent
[3H]E217G Uptake. The data obtained from substrate transport
studies ([3H]TC and [3H]E217G) in suspended hepatocytes were
plotted against the inhibitor concentration (S-sulfone and S-sulfide).
Based on standard model selection criteria including residual distri-
bution, Akaike’s information criterion, and visual inspection, the
sigmoidal inhibitory Emax model was selected to estimate the con-
centration for 50% inhibition of uptake (IC50) by using WinNonlin
5.0.1 (Pharsight, Mountain View, CA).
E  Emax  1  CrCr  IC50r (3)
where E is the rate of substrate uptake, Emax is the maximum rate of
substrate uptake, C is the inhibitor concentration, and r is the curve
shape factor.
Statistical Analysis. Data are expressed as mean and the associ-
ated S.D. or S.E.M., as indicated. Statistical differences were deter-
mined by one-way analysis of variance (ANOVA) with Bonferroni’s post
hoc test using SigmaStat 2.03 (Aspire Software International, Ashburn,
VA). Differences were considered significant at p  0.05.
Results
Effect of Sulindac and Metabolites on TC Hepatobili-
ary Disposition in Rat SCH. [3H]TC was used as a model
substrate to examine the impact of sulindac and metabolites
on the hepatic uptake and biliary excretion of bile acids in rat
SCH (Fig. 2). The accumulation of TC (1 M, 100 nCi/ml, 10
min) in cells  bile in the presence of 100 M S-sulfide was
significantly decreased compared with vehicle control. TC
BEI in the presence of 1 and 10 M sulindac, S-sulfone,
and S-sulfide was not statistically different from those
values in vehicle control. TC BEI was decreased signifi-
cantly by 100 M S-sulfone (42% decrease) and S-sulfide
(55% decrease), but TC BEI in the presence of 100 M
sulindac was not different from those values in vehicle
control. Sulindac (10 M; 53% decrease), S-sulfone (100
M; 76% decrease), and S-sulfide (100 M; 84% decrease)
significantly inhibited TC Clbiliary.
Effect of Sulindac and Metabolites on E217G Hepa-
tobiliary Disposition in Rat SCH. [3H]E217G was used as
a model substrate to examine the impact of sulindac and
metabolites on Oatp-mediated uptake and Mrp2-mediated
biliary excretion in rat SCH (Fig. 3). Accumulation of E217G
(1 M, 100 nCi/ml, 10 min) in cells  bile and cells was
decreased significantly in the presence of sulindac (100 M),
S-sulfone (10 and 100 M), and S-sulfide (10 and 100 M).
E217G BEI was not affected by sulindac, S-sulfone, or S-
sulfide (1–100 M), whereas E217G Clbiliary was decreased
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significantly by S-sulfone (1, 10, and 100 M) and S-sulfide
(100 M), but not by sulindac.
Effect of Sulindac and Metabolites on NF Hepatobili-
ary Disposition in Rat SCH. NF, a specific Bcrp substrate in
rat SCH (Yue et al., 2009), was used as a model substrate to
examine the impact of sulindac and metabolites on Bcrp-medi-



















































21 ± 7 19 ± 9 7.0 ± 2.0 4.1 ± 2.2
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BEI (%) 18 ± 3 10 ± 4 10 ± 3 13 ± 12



























CTL 1 10 100
E
0
BEI (%) 18 ± 2 12 ± 5 17 ± 3 18 ± 3
in vitro  Clbiliary
(ml/min/kg) 20 ± 3 12 ± 5 10 ± 3 0.7 ± 0.4*
in vitro  Clbiliary
in vitro  Clbiliary
Fig. 3. Effect of sulindac and metabolites on hepatobiliary disposition
of E217G in rat SCH. Accumulation of [3H]E217G (1 M, 100 nCi/ml,
10 min) in cells  bile (black bars) and cells (white bars) was measured
in the presence of increasing concentrations (1–100 M) of sulindac
(A), S-sulfone (B), or S-sulfide (C) in rat SCH. BEI and in vitro Clbiliary
of E217G were calculated as described under Materials and Methods.
Data are presented as the mean  S.E.M (n 
 3– 4 livers in triplicate);
, statistically different from vehicle control (CTL) by one-way ANOVA








































         
in vitro  Clbiliary
(ml/min/kg)
32 ± 5 26 ± 1a 15 ± 1 20 ± 3a*
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BEI (%) 82 ± 2 84 ± 2a 76 ± 3a 47 ± 12
in vitro  Clbiliary
(ml/min/kg)
























CTL 1 10 100
0
BEI (%) 83 ± 2 79 ± 2a 79 ± 2a 37 ± 17
in vitro  Clbiliary 
(ml/min/kg)
49 ± 8 32 ± 6b 31± 9b 7.5 ± 5.0
*
*
Fig. 2. Effect of sulindac and metabolites on hepatobiliary disposition of
TC in rat SCH. Accumulation of [3H]TC (1 M, 100 nCi/ml, 10 min) in
cells  bile (black bars) and cells (white bars) was measured in the
presence of increasing concentrations (1–100 M) of sulindac (A), S-
sulfone (B), or S-sulfide (C) in rat SCH. BEI and in vitro Clbiliary of TC
were calculated as described under Materials and Methods. Data are
presented as the mean  S.E.M (n 
 3–4 livers in triplicate); , statis-
tically different from vehicle control (CTL) by one-way ANOVA with
Bonferroni’s post hoc test.
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(5 M, 10 min) in cells  bile was not significantly different in
the presence of 100 M sulindac, S-sulfone, or S-sulfide, but
cellular accumulation was increased significantly in the pres-
ence of S-sulfide. NF BEI was decreased by 30, 39, and 57% in
the presence of 100 M sulindac, S-sulfone, and S-sulfide, re-
spectively, compared with vehicle control. Clbiliary of NF was
decreased, with more potent inhibition by S-sulfide (50% de-
crease), followed by sulindac (33% decrease) and S-sulfone (33%
decrease).
Influence of S-Sulfone and S-Sulfide on Na-Depen-
dent Initial Uptake of TC and Na-Independent Initial
Uptake of E217G in Suspended Rat Hepatocytes. To
further examine the mechanisms of inhibition of hepatic
transport proteins by sulindac metabolites, the inhibitory
potency of S-sulfone and S-sulfide on the initial uptake of
TC in the absence and presence of Na was determined in
suspended rat hepatocytes (Fig. 5, A and C, respectively).
Initial uptake was determined at 30 s for TC (1 M, 60
nCi/ml) based on preliminary studies (data not shown).
The IC50 values for inhibition of Na
-dependent TC initial
uptake by S-sulfone and S-sulfide were 24.9  6.4 M (Fig.
5B) and 12.5  1.8 M (Fig. 5D), respectively. E217G
initial uptake was determined under Na-free conditions
(Oatp-mediated) to exclude Na-dependent E217G uptake
by Ntcp (Kouzuki et al., 1999). Na-independent E217G
initial uptake (1 M, 60 nCi/ml, 90 s) was 114.8  33.1
pmol/mg protein/min, which was comparable with previous
data reported by Kemp et al. (2005). The IC50 values for
inhibition of Na-independent E217G initial uptake by
S-sulfone and S-sulfide were 12.1  1.6 M (Fig. 6A) and
6.3  0.3 M (Fig. 6B), respectively.
Effect of Sulindac and Metabolites on TC Hepatobili-
ary Disposition in Human SCH. In human SCH, [3H]TC
accumulation (1 M, 100 nCi/ml, 10 min) in cells  bile in
the presence of 10 and 100 M sulindac and S-sulfone was
comparable with vehicle control, but S-sulfide at 10 and
100 M inhibited TC accumulation by 52 and 87%, respec-
tively (Fig. 7). TC BEI was not decreased by sulindac,
S-sulfone, or S-sulfide, but 10 and 100 M S-sulfide de-
creased the Clbiliary of TC by 50 and 88%, respectively.
Influence of S-Sulfone and S-Sulfide on Na-Depen-
dent TC Initial Uptake in Suspended Human Hepato-
cytes. Based on previously published data demonstrating
that TC uptake was linear for at least 2 min in freshly
isolated human hepatocytes (Shitara et al., 2003), the in-
hibitory potency of S-sulfone and S-sulfide on the initial
uptake of [3H]TC (1 M, 60 nCi/ml) in the absence and
presence of Na was determined at 30 s in suspended
Fig. 4. Effect of sulindac and metabolites on hepatobiliary disposition of
NF in rat SCH. Accumulation of NF (5 M, 10 min) in cells  bile (black
bars) and cells (white bars) was measured in the presence of 100 M
sulindac, S-sulfone, or S-sulfide in rat SCH. BEI and in vitro Clbiliary of
NF were calculated as described under Materials and Methods. Data are
presented as the mean  S.E.M (n 
 3 livers in triplicate); , statistically
different from vehicle control (CTL) by one-way ANOVA with Bonferro-
ni’s post hoc test.
Fig. 5. Inhibition of Na-dependent TC
initial uptake in suspended rat hepato-
cytes by S-sulfone (A and B) and S-sulfide
(C and D). Na-dependent [3H]TC initial
uptake (1 M, 60 nCi/ml, 30 s) was deter-
mined by subtracting [3H]TC uptake in
Na-free buffer (E) from [3H]TC uptake
in Na-containing buffer (F) in the pres-
ence of increasing concentrations of S-
sulfone (0.5–100 M; A) and S-sulfide
(0.5–100 M; C). Symbols and error bars
represent the mean  S.D. of n 
 1–3
livers in duplicate. The dotted curve rep-
resents the best fit of the sigmoidal inhib-
itory Emax model to the data by using
WinNonlin (B and D); the curve shape
factor (r) was estimated as 0.31  0.04
and 0.81  0.09 for S-sulfone and S-sul-
fide, respectively.
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human hepatocytes (Fig. 8, A and C, respectively). The
IC50 for the inhibition of Na
-dependent TC initial uptake
by S-sulfone and S-sulfide was 42.2 M (Fig. 8B) and 3.1
M (Fig. 8D), respectively.
Effect of Sulindac and Metabolites on E217G Hepa-
tobiliary Disposition in Human SCH. In human SCH,
[3H]E217G accumulation (1 M, 100 nCi/ml, 10 min) in
cells  bile and cells was markedly decreased with 100 M
sulindac and metabolites (68 – 85% decrease) (Fig. 9). Con-
trary to rat SCH, E217G BEI was decreased in the pres-
ence of sulindac (74% decrease), S-sulfone (100% de-
crease), and S-sulfide (51% decrease). The Clbiliary of
E217G was decreased more than 85% by sulindac and
metabolites in human SCH.
Discussion
Among the NSAIDs, sulindac has been associated with the
highest incidence of DILI. One potential mechanism of DILI
may involve interference with hepatic transport protein func-
tion. The present study was designed to examine interactions
between sulindac/metabolites and hepatic transport proteins
by using TC, E217G, and NF as model substrates, respec-
tively, for Ntcp-/Bsep-, Oatp-/Mrp2-, and Bcrp-mediated
transport, respectively, in primary rat and human hepato-
cytes. BEI and Clbiliary from SCH were used as indices of
hepatobiliary disposition of each model substrate; BEI is a
measure of net canalicular efflux, whereas Clbiliary encom-
passes both uptake and efflux.
Both the BEI and Clbiliary of TC in rat SCH were decreased
significantly by S-sulfone and S-sulfide (100 M) (Fig. 2, B
and C). Moreover, both metabolites inhibited Na-dependent
TC initial uptake in suspended rat hepatocytes (IC50 of 24.9
and 12.5 M, respectively). Collectively, these data indicate
that S-sulfone and S-sulfide inhibit Ntcp and Bsep, as de-
picted in Fig. 10. The balance between bile acid uptake and
excretion in hepatocytes may influence the occurrence of
DILI. Indeed, the preferential inhibition of rat Ntcp com-
pared with human NTCP by bosentan may protect rats from
hepatotoxicity by preventing further uptake of bile acids
from blood when hepatocyte bile acid concentrations are in-
creased because of bosentan-mediated Bsep/BSEP inhibition
(Leslie et al., 2007).
In rats, E217G is taken up by multiple Oatps, whereas
biliary excretion of E217G is governed by Mrp2. The de-
creased hepatocellular accumulation of E217G in the pres-
ence of S-sulfone and S-sulfide in rat SCH, combined with
the inhibition of E217G Clbiliary but not BEI, suggested that
sulindac metabolites inhibited Oatp-mediated uptake but not
Mrp2-mediated biliary excretion of E217G (Fig. 3, B and C).
Subsequent investigations in suspended rat hepatocytes re-
vealed that S-sulfone and S-sulfide were potent inhibitors
(IC50 of 12.1 and 6.3 M, respectively) of E217G initial up-
take, consistent with the inhibition of Oatp 1a1 and 1a4
(Sugiyama et al., 2001).
NF was chosen as a model substrate for Bcrp-mediated
transport based on recent data demonstrating that NF is a
specific Bcrp substrate in rat SCH (Yue et al., 2009).
Several clinical studies have reported that genetic poly-
morphisms in BCRP (ABCG2) can influence drug disposi-
tion. For example, the ABCG2 C421A polymorphism is
associated with decreased protein expression and function
in vitro (Imai et al., 2002) and increased plasma concen-
Fig. 6. Inhibition of Na-independent E217G initial uptake in suspended
rat hepatocytes by S-sulfone (A) and S-sulfide (B). Na-independent
[3H]E217G initial uptake (1 M, 60 nCi/ml, 90 s) was determined in
Na-free buffer in the presence of increasing concentrations of S-sulfone
(0.5–100 M) and S-sulfide (0.5–100 M). Symbols and error bars repre-
sent the mean  S.D. of n 
 3 livers in duplicate. The dotted curve
represents the best fit of the sigmoidal inhibitory Emax model to the data
by using WinNonlin; the curve shape factor (r) was estimated as 0.8  0.2





























Sulindac (µM) S-sulfone (µM) S-sulfide (µM)
BEI (%) 59 57 44 54 52 60 49
in vitro  Clbiliary 
(ml/min/kg) 27 22 18 19 21 13 3.3
Fig. 7. Effect of sulindac and metabolites on hepatobiliary disposition of
TC in human SCH. Accumulation of [3H]TC (1 M, 100 nCi/ml, 10 min)
in cells  bile (black bars) and cells (white bars) was measured in the
presence of 10 and 100 M sulindac, S-sulfone, or S-sulfide in human
SCH. BEI and in vitro Clbiliary of TC were calculated as described under
Materials and Methods. Bars and error bars denote mean  one-half the
range from n 
 2 livers in duplicate.
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trations of several BCRP substrates, including rosuvasta-
tin, diflomotecan, and sulfasalazine (Morisaki et al., 2005;
Zhang et al., 2006; Yamasaki et al., 2008). In the present
study, sulindac/metabolites significantly decreased NF
BEI and Clbiliary in rat SCH, consistent with the inhibition
of Bcrp (Fig. 4), suggesting the potential for BCRP-medi-
ated interactions when sulindac is administered with
other drugs/xenobiotics. Investigations are underway to
determine whether sulindac and metabolites alter human
BCRP-mediated transport.
TC was tested further in human SCH to examine whether
sulindac/metabolites also inhibited the hepatic transport of
TC. In human SCH, TC accumulation in cells  bile and the
TC Clbiliary were decreased markedly by S-sulfide without
affecting TC BEI. These findings may reflect, at least in part,
S-sulfide-mediated inhibition of NTCP. The IC50 (3.1 M) of
Na-dependent TC initial uptake by S-sulfide determined in
human hepatocyte suspensions, which do not contain serum,
was near the unbound plasma concentration range of S-
sulfide (0.14–1.5 M) based on reported Cmax values of 3 to
33 M and an unbound fraction (fu) of 4.6% after oral admin-
istration of a therapeutic dose of sulindac (Davies and Mor-
ris, 1993). However, the IC50 (42.2 M) of Na
-dependent TC
initial uptake by S-sulfone was 100-fold greater than the
unbound plasma concentration range (0.1–0.4 M) of S-
sulfone (Cmax, 4–19 M; fu, 2.1%). Although the IC50 for
inhibition of Na-dependent TC initial uptake by S-sulfone
was higher than unbound plasma concentrations, it is prob-
able that the initial inhibitor concentrations in the portal
vein when sulindac is administered orally are higher than
unbound plasma concentrations, because 85% of total he-
patic blood flow is composed of portal venous blood, which
contains drug absorbed directly from the gastrointestinal
tract (Ito et al., 1998). In addition, it is plausible that the
extensive enterohepatic recycling of sulindac and metabolites
may result in prolonged inhibition of hepatic transport pro-
teins caused by much higher concentrations in the portal
circulation (Dujovne et al., 1983).
The Food and Drug Administration has recommended an
in vivo evaluation of drug interactions when the estimated
[I]/Ki ratio is more than 0.1, where [I] represents the mean
steady-state Cmax value for total drug (bound plus unbound)
after administration of the highest proposed clinical dose
(Huang et al., 2008). In theory, the IC50 values determined in
the present study would be identical to Ki values, regardless
of the mechanism of inhibition, based on previous data dem-
Fig. 8. Inhibition of Na-dependent TC
initial uptake in suspended human hepa-
tocytes by S-sulfone (A and B) and S-
sulfide (C and D). Na-dependent [3H]TC
initial uptake (1 M, 60 nCi/ml, 30 s) was
determined by subtracting [3H]TC up-
take in Na-free buffer (open symbols;
n 
 2 livers) from those values in Na-
containing buffer (closed symbols; n 
 2
livers) in the presence of increasing con-
centrations of S-sulfone (0.5–300 M; A)
and S-sulfide (0.5–100 M; C). X and 
denote individual data from n 
 2 livers
in duplicate (B and D). The dotted curve
represents the best fit of the sigmoidal
inhibitory Emax model to the data by us-
ing WinNonlin; the curve shape factor (r)
was estimated as 0.6 and 0.9 for S-sulfone
and S-sulfide, respectively.
Fig. 9. Effect of sulindac and metabolites on hepatobiliary disposition of
E217G in human SCH. Accumulation of [3H]E217G (1 M, 100 nCi/ml, 10
min) in cells  bile (solid bars) and cells (empty bars) was measured in
the presence of 100 M sulindac, S-sulfone, or S-sulfide in human SCH.
BEI and in vitro Clbiliary of E217G were calculated as described under
Materials and Methods. Bars and error bars denote mean  half the
range from n 
 2 livers in duplicate.
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onstrating the relationships between the Ki and IC50 values
(Cheng and Prusoff, 1973); that is, the Ki value is equal to the
IC50 value under conditions of either noncompetitive or un-
competitive inhibition, whereas under competitive inhibition
conditions, the IC50 value will be identical to Ki(1  S/Km),
where S is the substrate concentration and Km is the sub-
strate concentration corresponding to one-half of the maxi-
mal velocity of the reaction. Because the TC concentration (1
M) used for the IC50 determination in the present study was
lower than the previously reported Km value for the uptake of
TC in rat (18 M) and human (4.8 M) hepatocytes, the Ki
values would be equal to or less than the IC50 value (Kouzuki
et al., 1998; Shitara et al., 2003). With this assumption, the
[I]/Ki ratio determined by using data from human hepato-
cytes ranged from 0.9 to 10.6 for S-sulfide and 0.1 to 0.4 for
S-sulfone, based on Cmax values of 3 to 33 and 4 to 19 M,
respectively (Davies and Morris, 1993). These findings sug-
gest that S-sulfide and S-sulfone may interact with NTCP-
mediated transport of bile acids and/or drugs in humans.
In human SCH, the hepatic uptake of E217G was de-
creased markedly in the presence of 100 M sulindac and
metabolites, suggesting a potential interaction between su-
lindac/metabolites and other drugs that are transported by
OATPs (OATP1B1 and OATP1B3). Because of the limited
availability of human liver tissue, the IC50 of E217G initial
uptake by sulindac/metabolites was not determined. It is
noteworthy that, contrary to rat SCH, sulindac and its me-
tabolites markedly decreased the biliary excretion index of
E217G (a substrate for MRP2) in human SCH, consistent
with previous data demonstrating inhibition of MRP2-medi-
ated methotrexate transport by sulindac in MRP2-overex-
pressing membrane vesicles (El-Sheikh et al., 2007). This
discrepancy may be caused by species differences in canalic-
ular transport mechanisms between rats and humans, which
requires further characterization (Li et al., 2009).
In conclusion, the present studies demonstrated that mul-
tiple hepatic transport proteins (Ntcp/NTCP, Oatp/OATP,
Bsep, Bcrp, or MRP2) are inhibited by sulindac and metab-
olites. Impaired hepatic transport of bile acids by sulindac/
metabolites may disturb bile acid homeostasis, resulting in
sulindac-mediated liver injury. Furthermore, interactions
between sulindac/metabolites and drugs that are sub-
strates for these transport proteins may result in clinically
significant interactions. For example, Furst et al. (1990)
demonstrated that oral administration of sulindac de-
creased methotrexate clearance in patients with rheuma-
toid arthritis. Considering that methotrexate is taken up
by OATP1B1 and OATP1B3 and excreted by MRP2 in the
human liver, the interaction between sulindac and meth-
otrexate may be caused by the sulindac-mediated inhibi-
tion of these transport proteins, as depicted in Fig. 10. The
possibility of hepatic transporter-mediated interactions
should be considered when sulindac is coadministered with
other drugs/xenobiotics.
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